{
  "id": "51542eacd24251bc05000084",
  "type": "yesno",
  "question": "Does HER2 under-expression lead to favorable response to trastuzumab?",
  "ideal_answer": "No, trastuzumab is effective only in cancers where Her2 is over-expessed.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/22711713",
    "http://www.ncbi.nlm.nih.gov/pubmed/20392785",
    "http://www.ncbi.nlm.nih.gov/pubmed/23082154",
    "http://www.ncbi.nlm.nih.gov/pubmed/19606230",
    "http://www.ncbi.nlm.nih.gov/pubmed/12503030",
    "http://www.ncbi.nlm.nih.gov/pubmed/21709140",
    "http://www.ncbi.nlm.nih.gov/pubmed/19624808",
    "http://www.ncbi.nlm.nih.gov/pubmed/18534031",
    "http://www.ncbi.nlm.nih.gov/pubmed/19435924",
    "http://www.ncbi.nlm.nih.gov/pubmed/22580986",
    "http://www.ncbi.nlm.nih.gov/pubmed/11148461",
    "http://www.ncbi.nlm.nih.gov/pubmed/19920112",
    "http://www.ncbi.nlm.nih.gov/pubmed/22658319"
  ],
  "snippets": [
    {
      "text": "over-expression of HER2 is reported in approximately 20% of gastric tumours, challenging the use of targeted therapies. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22711713",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "In patients with advanced gastric or gastro-oesophageal junction cancer, addition of trastuzumab to chemotherapy significantly improved overall survival compared with chemotherapy alone. Addition of trastuzumab to chemotherapy did not increase the incidence of adverse events.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22711713",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "treatment of HER2-overexpressing breast cancer: trastuzumab,",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22658319",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Trastuzumab has demonstrated clinical activity in several types of HER2-overexpressing epithelial tumors, such as breast and metastatic gastric or gastroesophageal junction cancer. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22580986",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "An example is the established benefit of trastuzumab as adjuvant therapy for breast cancer; a clear definition of HER2-positivity and the assay reproducibility have, however, remained unanswered. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20392785",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Trastuzumab is a monoclonal antibody targeted to the Her2 receptor and approved for treatment of Her2-positive breast cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19920112",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Human epidermal growth factor receptor 2 (HER2/neu) is an important target for the treatment of the breast cancers in which it is overexpressed. However, no approved anti-HER2/neu therapy is available for the majority of breast cancer patients, who express HER2/neu at low levels (with scores of 1+ or 2+/fluorescence in situ hybridization-negative).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19435924",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "The humanized anti-HER2 monoclonal antibody trastuzumab (Herceptin) is useful in the treatment of ErbB2-overexpressing breast cancers,",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12503030",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "HercepTestTM (DAKO A/S, Glostrup, Denmark) is an immunohistochemical assay that detects HER2/neu gene products, and evaluates the overexpression status of the HER2/neu protein in determining eligibility for the Trastuzumab (HerceptinR, Genentech, San Francisco, CA, USA) therapy. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11148461",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    }
  ],
  "concepts": [
    "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015870",
    "http://www.disease-ontology.org/api/metadata/DOID:0060079",
    "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020869",
    "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0010467",
    "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018734",
    "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0038128",
    "http://www.biosemantics.org/jochem#4002084",
    "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0005176",
    "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005786",
    "http://www.disease-ontology.org/api/metadata/DOID:0060080"
  ],
  "exact_answer": "Yes"
}